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Abstract
Background: Surfactant protein C (SP-C) is important for the function of pulmonary surfactant. Heterozygous
mutations in SFTPC, the gene encoding SP-C, cause sporadic and familial interstitial lung disease (ILD) in children
and adults. Mutations mapping to the BRICHOS domain located within the SP-C proprotein result in perinuclear
aggregation of the proprotein. In this study, we investigated the effects of the mutation A116D in the BRICHOS
domain of SP-C on cellular homeostasis. We also evaluated the ability of drugs currently used in ILD therapy to
counteract these effects.
Methods: SP-C
A116D was expressed in MLE-12 alveolar epithelial cells. We assessed in vitro the consequences for
cellular homeostasis, immune response and effects of azathioprine, hydroxychloroquine, methylprednisolone and
cyclophosphamide.
Results: Stable expression of SP-C
A116D in MLE-12 alveolar epithelial cells resulted in increased intracellular
accumulation of proSP-C processing intermediates. SP-C
A116D expression further led to reduced cell viability and
increased levels of the chaperones Hsp90, Hsp70, calreticulin and calnexin. Lipid analysis revealed decreased
intracellular levels of phosphatidylcholine (PC) and increased lyso-PC levels. Treatment with methylprednisolone or
hydroxychloroquine partially restored these lipid alterations. Furthermore, SP-C
A116D cells secreted soluble factors
into the medium that modulated surface expression of CCR2 or CXCR1 receptors on CD4
+ lymphocytes and
neutrophils, suggesting a direct paracrine effect of SP-C
A116D on neighboring cells in the alveolar space.
Conclusions: We show that the A116D mutation leads to impaired processing of proSP-C in alveolar epithelial
cells, alters cell viability and lipid composition, and also activates cells of the immune system. In addition, we show
that some of the effects of the mutation on cellular homeostasis can be antagonized by application of
pharmaceuticals commonly applied in ILD therapy. Our findings shed new light on the pathomechanisms
underlying SP-C deficiency associated ILD and provide insight into the mechanisms by which drugs currently used
in ILD therapy act.
Background
Pulmonary surfactant is a phospholipid/protein mixture
secreted to the alveolar surface by alveolar type 2 (AT2)
cells [1]. It reduces surface tension and prevents alveolar
collapse at the end of expiration [2]. A normal composi-
tion and homeostasis of pulmonary surfactant is critical
for its surface-tension-reducing properties and gas
exchange in the alveoles of the lung. Surfactant protein
C (SP-C) is a hydrophobic, lung-specific protein that
coisolates with the phospholipid fraction of pulmonary
surfactant [3]. SP-C is synthesized exclusively by AT2
cells as a 197 amino acid proprotein (proSP-C) and pro-
teolytically processed into the 4.2 kDa mature protein
by a sequence of proteolytic cleavages [4]. Mature SP-C
is subsequently secreted together with lipids and other
surfactant components to the alveolar surface [3,5]. AT2
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any medium, provided the original work is properly cited.cells contain specialized lysosome-derived organelles for
the storage of surfactant prior to its secretion. Exocyto-
sis is facilitated by fusion of these so-called lamellar
bodies (LBs) with the plasma membrane [6]. The
SNARE proteins syntaxin 2 and SNAP-23 are associated
with the plasma membrane and to some degree with
lamellar bodies and have been shown to be required for
regulated surfactant secretion [7,8].
Interstitial lung diseases (ILD) are a heterogeneous
group of respiratory disorders that can be classified into
those with known and unknown etiologies [9]. ILD are
characterized by deposition of cellular and non-cellular
components into the lung parenchyma. They vary widely
in regard to radiological presentation, histopathological
features, and clinical course [10]. ILD are mostly chronic
and associated with high morbidity and mortality. Typi-
cal features of ILD include dyspnoea, the presence of
diffuse infiltrates on chest radiographs and abnormal
pulmonary function tests with evidence of a restrictive
ventilatory defect and/or impaired gas exchange [11].
Mutations in the surfactant protein genes SFTPB and
SFTPC as well as in the ABC-transporter coding gene
ABCA3, all of them resulting in a disturbed lung surfac-
tant homeostasis, have been identified as genetic causes
in some forms of ILD [12-16]. While loss-of-function
mutations in SP-B result in surfactant deficiency and
fatal neonatal lung disease, consequences of mutations in
SP-C tend to be less severe, ranging from fatal pulmonary
surfactant deficiency to childhood ILD [17]. Most SP-C
mutations cluster within the preprotein’sB R I C H O S
domain and lead to misfolding of the preprotein, aberrant
trafficking and processing [3]. To date, all affected indivi-
duals with BRICHOS domain mutations have been het-
erozygous with no detectable mature SP-C in their lungs,
suggesting a dominant-negative effect of the mutant
allele [3,12]. Moreover, in cell lines expressing BRICHOS
domain mutations, proSP-C forms perinuclear aggre-
gates, consistent with the cell’s inability to clear aggre-
gates of misfolded protein and a toxic gain-of-function
[12,18]. Accumulation of misfolded proSP-C may trigger
several distinct pathological mechanisms, such as induc-
tion of endoplasmic reticulum (ER) stress, cytotoxicity,
and caspase 3- and caspase 4-mediated apoptosis
[14,19,20]. These factors might contribute to ILD by
causing cell injury and apoptotic death of AT2 cells.
Current treatment of ILD in children is unfortunately
empirical. Since an inflammatory component is present
in ILD, corticosteroids and immunosuppressive drugs
like azathioprine are used in ILD therapy [21]. Corticos-
teroids are anti-inflammatory and stimulate surfactant
protein transcription [22,23]. While chloroquine and its
less toxic derivative hydroxychloroquine are also used in
ILD treatment, their mode of action remains controver-
sial [21,24]. It has been proposed that chloroquine acts
on lysosomal function or stimulates the generation of
lamellar bodies [25,26]. Thus, there is obviously an
urgent need to define the target mechanism of the treat-
ments currently applied in ILD therapy.
Cell chaperones which assist in normal protein folding
and removal of misfolded proteins may pose promising
therapeutic targets in ILD [27]. For example, the SFTPC
mutation Δexon4 leads to accumulation of misfolded SP-
C and a subsequent upregulation the major ER chaperone
GRP78/BiP in an attempt to maintain surfactant biosynth-
esis in the presence of ER stress [19]. Pharmacological
intervention in order to increase the expression of GRP78
or other chaperones, like Hsp90, Hsp70, calreticulin and
calnexin, may be suitable to counteract the deleterious
effects of the accumulation of aberrant protein in the cells.
We hypothesized that pharmaceuticals currently used
in ILD therapy may operate by counteracting distur-
bances of cellular homeostasis caused for example by
mutations in SP-C. Therefore, the aim of the present
study was to investigate the intracellular alterations in
alveolar epithelial cells expressing SP-C
A116D and the
ability of pharmaceuticals commonly used in ILD therapy
to modulate the effects caused by mutant SP-C. The
A116D mutation was chosen as a representative of the
BRICHOS domain mutations. It was described at first in
ab o yw i t hs e v e r er e s p i r a t o r yd i s t r e s sa n dad i a g n o s i so f
nonspecific interstitial pneumonitis [28]. We studied the
impact of the A116D mutation on proSP-C processing,
cellular stress tolerance, lipid composition, and immu-
nity. In addition, we investigated modulation of the cellu-
lar pathomechanisms by pharmaceutical drugs currently
applied in ILD therapy.
Methods
Plasmid vectors
Eukaryotic expression vectors containing the full human
SFTPC gene fused to either EGFP-tag (pEGFP-N1/hSP-
C1-197 and pEGFP-C1/hSP-C1-197 to obtain proSP-C
with EGFP fused to the C- or N-terminus, respectively) or
hemagglutinin (HA)-tag (proSP-C with N-terminal HA-
tag) were obtained as previously described [12]. The
A116D point mutation was introduced into the wild-type
(WT) SFTPC gene in these vectors using the Quick-
Change site-directed mutagenesis kit (Stratagene, La Jolla,
USA) and the following primers: A116D_forward: 5’-GCC
TAC AAG CCA GAC CCT GGC ACC TGC-3’,
A116D_reverse: 5’-GCA GGT GCC AGG GTC TGG
CTT GTA GGC-3’, following the manufacturer’sp r o t o c o l .
The successful mutagenesis was confirmed by Sanger
sequencing.
MLE-12 cell lines and transfection
The mouse MLE-12 lung epithelial cell line (CRL-2119)
[29] was obtained from the American Type Culture
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supplemented with 10% fetal bovine serum. Cells were
transfected using FuGene 6 (Roche, Penzberg, Germany)
according to the manufacturer’s instructions. MLE-12
cells stably transfected with either pcDNA3/HA-hSP-
C1-197 or pcDNA3/HA-hSP-CA116D vectors were
obtained by selecting transfected cells in the presence of
600 μg/ml G418 in RPMI medium for four weeks. For
drug exposure experiments, stable cells were grown for
24 hours in the presence of 10 μM of cyclophospha-
mide, azathioprine, methylprednisolone or hydroxychlor-
oquine. Untreated cells that were cultured in parallel
served as controls.
Immunoblotting
Total cell proteins were obtained by lysing the cells in
lysis buffer [PBS, 20 mM EDTA, 1% v/v Elugent (Cal-
biochem, Bad Soden, Germany), protease inhibitor
(Complete; Roche, Manheim, Germany)]. For immuno-
blotting, 30 μg protein was separated under reducing
conditions using 10% NuPage Bis-Tris gels (Invitrogen,
Karlsruhe, Germany) and transferred to a PVDF mem-
brane. The following primary antibodies were used:
monoclonal rat anti-HA-tag (1:1000; Roche), monoclo-
nal mouse anti-GFP (1:500; Clontech, Heidelberg, Ger-
many), and polyclonal goat anti-calnexin (1:500),
polyclonal goat anti-calreticulin (1:500), monoclonal
mouse anti-HSP90a/b, polyclonal goat anti-HSP70
(1:1000), and monoclonal anti-b-actin HRP conjugate
(1:10000) (all from Santa Cruz Biotechnology, Santa
Cruz, CA). Signal was detected using chemiluminescent
labeling with Amersham ECL Detection Reagents (GE
Healthcare), densitometrically quantified and normalized
to the b-actin signal.
Immunofluorescence
24 hours after transfection, cells grown on coverslips
were fixed with 4% paraformaldehyde, permeabilised
with 10% Triton X-100, and blocked for 30 min in PBS
with 5% FBS. The following primary antibodies were
used in 1:200 dilution: polyclonal rabbit anti-mouse
LAMP3 (Santa Cruz), monoclonal mouse anti-human
CD63/LAMP3 (Chemicon, Schwalbach, Germany), poly-
clonal rabbit anti-EEA1 (Acris Antibodies, Herford, Ger-
many), monoclonal mouse anti-ubiquitin (Biomol,
Hamburg, Germany) and polyclonal rabbit anti-syntaxin
2 (Synaptic Systems, Berlin, Germany). Species specific
Alexa Fluor 488 or Alexa Fluor 555 secondary antibo-
dies (Invitrogen) were used at 1:200. Samples were
mounted and Alexa Fluor or GFP fluorescence was
examined with Axiovert 135 fluorescent microscope and
evaluated with AxioVision 4.7.1 software (Carl Zeiss,
Jena, Germany).
Lactate dehydrogenase (LDH) assay
LDH activity in cell lysates and culture supernatants was
determined using the method of Decker and Lohmann-
Matthes [30]. Briefly, 100 μl sample was mixed with 30 μl
dye solution (18 mg/ml L-lactate, 1 mg/ml iodonitrotetra-
zolium in PBS). After adding 15 μl of the catalyst (3 mg/
ml NAD
+, 2.3 mg/ml diaphorase, 0.03% BSA, 1.2% sucrose
in PBS), absorbance at 492 nm was determined at one
minute intervals for 15 minutes at 37°C. Absolute LDH
activity was calculated from a standard curve, using puri-
fied LDH (Sigma, Munich, Germany). The lower limit of
detection was 20 Units/l; the assay was linear to 2500
Units/l.
Mass spectrometric lipid analysis
For lipid analysis, cells grown in Petri dishes were har-
vested by scraping off in 2 ml PBS supplemented with pro-
tease inhibitor (Complete, Roche). The cell suspension was
then sonicated (four strokes, 10 seconds; Branson Digital
Sonifier S450D). Lipid classes and subspecies were deter-
mined by electrospray ionization tandem mass spectrome-
try (ESI-MS/MS) using direct flow injection analysis, as
described previously [31,32]. Cells were extracted accord-
ing to the method described by Bligh and Dyer [33] in the
presence of non-naturally occurring lipid species used as
internal standards. A precursor ion scan of m/z 184 speci-
fic for phosphocholine containing lipids was used for
phosphatidylcholine (PC), sphingomyelin (SPM) [32] and
lysophosphatidylcholine (LPC) [31]. Neutral loss scans of
m/z 141 and m/z 185 were used for phosphatidylethanola-
mine (PE) and phosphatidylserine (PS), respectively [34].
Phosphatidylglycerol (PG) was analyzed using a neutral
loss scan of m/z 189 of ammonium adduct ions [35]. Cera-
mide and glucosylceramide were analyzed as previously
described [36] using N-heptadecanoyl-sphingosine as
internal standard. Quantification was achieved by calibra-
tion lines generated by addition of naturally occurring
lipid species to pooled cell homogenate. All lipid classes
were quantified with internal standards belonging to the
same lipid class, except SM (PC internal standards). Each
lipid class was calibrated with a variety of species covering
chain lengths and number of double bonds of naturally
occurring species. Correction of isotopic overlap of lipid
species and data analysis was performed by self-pro-
grammed Excel macros for all lipid classes according to
the described principles [32].
Flow cytometry
Human lymphocytes and neutrophils were isolated from
whole blood using LeucoSep (Greiner Bio-One, Solingen-
Wald, Germany) and Ficoll-Isopaque gradient density
isolation method (GE Healthcare) according to the man-
ufacturer’s instructions. Cells were incubated for 6 hours
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supernatants of MLE-12 cells expressing wild-type or
mutant proSP-C. Cell-free supernatants were collected
after 48 hours of growth and concentrated 7-fold, using
Microsep 1 k centrifugal concentrators (Millipore,
Schwalbach, Germany). Cells were analyzed by four-
colour flow cytometry (FACSCalibur; BD Biosciences,
Heidelberg, Germany) as described previously [37]. The
following antibodies were used: PE-conjugated mouse
anti-human CCR2-B (R&D Systems, Minneapolis, USA),
FITC labeled anti-human CD8, FITC labeled anti-human
CD4, PE-conjugated mouse anti-human CD11b/Mac-1,
and PE-conjugated mouse anti-human CD181 (CXCR1,
IL-8RA) (all BD Biosciences Pharmingen). Results are
presented as mean fluorescence intensity (MFI) after sub-
tracting background binding provided by non-specific
isotypes. Calculations were performed with CellQuest
analysis software (BD Biosciences).
Statistical methods
The results are given as means ± standard error (SE) of
the individual number of different subjects, each individual
value representing the mean of 3-4 determinations or as
indicated. In the case of lipid analysis, the results are pre-
sented as means ± standard deviation. For the comparison
of two groups, unpaired t-test or Mann-Whitney test were
used where appropriate. Comparisons of multiple groups
were made using ANOVA followed by Dunnett’s post hoc
multiple comparisons test. For correlations, Spearman’s
non-parametric test was used. P-values of less than 0.05
were considered as statistically significant. All tests were
performed using GraphPad Prism 4.0 (GraphPad
Software).
Results
MLE-12 cells process proSP-C
A116D differently from proSP-
C
WT and accumulate proSP-C
A116D processing
intermediates
To identify the intracellular processing intermediates of
proSP-C, MLE-12 cells were transfected with eukaryotic
expression vectors, allowing expression of fusion proteins
between proSP-C and either an EGFP- or a HA-Tag.
Stable expression of HA-tagged proSP-C
WT resulted in
the appearance of a strong band at approximately 21 kDa
and weaker bands at 22 kDa, 19 kDa, and 14 kDa (Figure
1A left). ProSP-C
A116D yielded bands similar to the wild
type at 21 kDa and 14 kDa. We also observed a much
stronger band at 22 kDa and a band at 15 kDa that was
not seen in the wild type, indicating accumulation of
proSP-C
A116D forms (Figure 1A, left). The postulated
processing products are depicted in Figure 1B. Mature
SP-C was never detectable because of the loss of the pro-
tein tag due to the final processing steps at the N-
terminus.
Transient expression of N-terminal (C1) and C-terminal
(N1) EGFP fusion products was detectable 24 hours post
transfection. The primary N- and C-terminal fusion pro-
teins were visible as bands at 48 kDa as expected. In the
case of N-terminally tagged protein, a second band was
seen at 36 kDa (Figure 1A, middle). There were no differ-
ences regarding band pattern between proSP-C
WT and
proSP-C
A116D. Likewise, no differences in band pattern
between proSP-C
WT and proSP-C
A116D were seen for pro-
cessing intermediates containing the C-terminal EGFP-tag
(Figure 1A right). This suggested that there was no change
in the cleavage pattern or kinetics regarding the truncation
of proSP-C from the C-terminus, which is supposed to be
the first cleavage step [4]. The lowest band corresponded
to the EGFP-tag, which has a size of approximately
27 kDa.
ProSP-C
A116D localizes to different intracellular
compartments than proSP-C
WT
The intracellular localization of preprotein species, moni-
tored by immunofluorescence, differed between MLE-12
cells stably expressing proSP-C
WT or proSP-C
A116D.
While HA-tagged proSP-C
WT colocalized well with syn-
taxin 2, proSP-C
A116D did not (Figure 2A). In contrast,
EGFP-tagged proSP-C
A116D was partially present in early
endosomes detected as EEA1-positive vesicles, while
proSP-C
WT was almost absent in those compartments
(Figure 2B), thus confirming previous data [38]. Again,
with this approach mature SP-C was not detectable
because of the loss of the tag due to processing.
Expression of SP-C
A116D increases susceptibility of MLE-12
cells to exogenous stress imposed by pharmacological
substances
In order to determine the stress level of cells expressing
SP-C
A116D, lactate dehydrogenase (LDH) release of stably
transfected cells was measured. Expression of SP-C
A116D
led to a marked overall increase of LDH release, com-
pared to WT cells, suggesting a reduction of cell viability
(Figure 3). Exposure of MLE-12 cells expressing SP-C
WT
to pharmacological substances currently applied in ILD
therapy significantly increased the release of LDH by the
cells in the case of azathioprine. While azathioprine treat-
ment resulted in a pronounced increase in LDH release
also in cells expressing SP-C
A116D, hydroxychloroquine,
methylprednisolone and cyclophosphamide did not sig-
nificantly alter LDH release by these cells.
Modulation of chaperone level in cells expressing SP-C
WT
and SP-C
A116D by pharmacological substances
We determined the change in protein level of the two
heat shock proteins Hsp90 and Hsp70, and the two ER-
resident chaperones calreticulin and calnexin, in MLE-12
cells expressing SP-C
WT and SP-C
A116D,a f t e re x p o s u r e
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cyclophosphamide, azathioprine, methylprednisolone or
hydroxychloroquine (Figure 4A-D). While in the case of
calnexin no significant alterations were seen, cells
expressing SP-C
A116D showed an increase in the expres-
sion of calreticulin, Hsp70 and Hsp90 at baseline and
after treatment with pharmaceuticals. However, none of
the applied drugs resulted in a significant change in
Figure 1 Processing features of proSP-C
WT or proSP-C
A116D. (A) Immunoblotting of total cell lysates with tag-specific antibodies. Cell lysates
obtained from MLE-12 cells stably expressing fusion protein of proSP-C with an N-terminal HA-tag (left panel), transiently transfected cells
expressing fusion protein of proSP-C with an N-terminal EGFP (EGFP-C1, middle panel) or a C-terminal EGFP (EGFP-N1, right panel), present with
several bands corresponding to different proSP-C processing intermediates, in which the tag sequence is retained. (B) Based on the size of the
bands, the projected corresponding intermediate species of the fusion constructs are depicted. The cleavage sites are only estimates due to the
limited resolution of the technique. EGFP-C1 (band #5) and EGFP-N1 (band #9) are expressed as a full-length product of 48 kDa, HA-SP-C (band
#1) of size 22 kDa.
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WT and proSP-C
A116D forms in stabile MLE-12 cells. Immunofluorescent analysis with an
antibody against (A) EEA1 (red) and (B) syntaxin 2 (red) shows that while proSP-C
WT localized with syntaxin 2, a protein found within lamellar
bodies as surfactant secretory vesicles, colocalization of proSP-C
A116D with syntaxin 2 was merely absent. ProSP-CA116D instead localized with in
EEA1 which did not show any colocalization with proSP-C
WT. Nuclei are stained with DAPI (blue).
Zarbock et al. BMC Pulmonary Medicine 2012, 12:15
http://www.biomedcentral.com/1471-2466/12/15
Page 6 of 13expression level of any chaperone, neither in cells expres-
sing SP-C
WT nor in cells expressing SP-C
A116D. However,
we noted a slight increase in the expression levels of
Hsp70 and Hsp90 in SP-C
A116D cells treated with
azathioprine (Figure 4C+D).
Alterations in the intracellular lipid composition and
composition of secreted lipids due to expression of SP-
C
A116D and their response to pharmacological treatment
Mass spectrometric lipid analysis showed that total
phospholipid amount was reduced in cell lysates from
MLE-12 cells transfected with SP-C
A116D, compared to
cells transfected with SP-C
WT (Table 1). Moreover, the
phospholipid composition was significantly altered: the
percentage of phosphatidylcholine (PC) and ceramide
(Cer) were significantly decreased while the percentages
of lyso-phosphatidylcholine (LPC), phosphatidylserine
(PS), phosphatidylethanolamine (PE) and sphingomyelin
(SPM) were significantly increased in cells expressing
SP-C
A116D. Treatment with methylprednisolone or
hydroxychloroquine did not correct the loss of PC
in SP-C
A116D expressing cells, although a significant
Figure 3 Viability of MLE12 cells expressing SP-C
WT or SP-
C
A116D before and after treatment with drugs used in therapy.
MLE-12 cells stably expressing SP-C
WT or SP-C
A116D were incubated
for 24 hours with 10 μM each of cyclophosphamide (+Cyc),
azathioprine (+Aza), methylprednisolone (+Met), or
hydroxychloroquine (+Hyd). LDH release, a sign of decreased cell
fitness, of treated vs. untreated (-) cells is expressed as % of total
LDH. Only significant p-values are depicted.
Figure 4 Modulation of chaperone levels in the cells expressing SP-C
WT and SP-
A116D by pharmacologic substances.S h o w ni st h e
expression relative to b-actin of the chaperone proteins calnexin (A), calreticulin (B), Hsp70 (C) and Hsp90 (D) in MLE-12 cells expressing proSP-
C
WT or proSP-C
A116D and either untreated (-) or exposed to cyclophosphamide (Cyc), azathioprine (Aza), methylprednisolone (Met), or
hydroxychloroquine (Hyd). Only significant p-values are presented.
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hydroxychloroquine (Figure 5A, left chart). Treatment
with methylprednisolone as well as with hydroxychloro-
quine led to a significant reduction of increased LPC
levels in cells expressing SP-C
A116D (Figure 5A, right
chart). The effect was more pronounced in the case of
hydroxychloroquine.
The phospholipid secretion by MLE-12 cells was
assessed in the supernatant (Table 1). Similar to the intra-
cellular lipid pattern, PC and Cer were significantly
decreased in the supernatant of SP-C
A116D cells, while the
percentages of LPC and SPM were increased. In contrast
to the findings in cell lysate, PE was not altered in the
supernatant of SP-C
A116D cells. Remarkably, PS was signif-
icantly decreased in the supernatant while being increased
in cell lysate of SP-C
A116D cells. PC levels in the superna-
tant of cells treated with methylprednisolone were elevated
compared to untreated cells by tendency, in WT as well as
in A116D cells. A significant increase in LPC secretion
was noted in cells expressing SP-C
A116D (Table 1; Figure
5B, right chart). Treatment with hydroxychloroquine, but
not with methylprednisolone, restored LPC level in the
supernatant of mutant SP-C expressing cells to the level
observed in WT cells. Interestingly, hydroxychloroquine
also reduced LPC in the supernatant of WT cells, albeit
not significantly. Taken together, hydroxychloroquine
treatment seems to be able to counteract the alterations of
PC and LPC levels seen in cells expressing SP-C
A116D.
MLE-12 cells expressing SP-C
A116D secrete factors that
stimulate surface expression of CCR-2 and CXCR-1 on
CD4+ lymphocytes and of CXCR-1 on neutrophils
We hypothesized that accumulation of misfolded SP-C
might somehow lead to an enhanced accumulation of
leukocytes and thus boost the inflammatory reaction. To
test this hypothesis, we examined whether cells
expressing SP-C
A116D stimulated the expression of
CCR2 on lymphocytes and CXCR1 on neutrophils by
incubating isolated neutrophils or lymphocytes with 7-
fold concentrated supernatants of MLE-12 cells expres-
sing either WT or A116D SP-C. While no difference in
surface receptor expression between WT and mutant
was observed in CD8+ lymphocytes, CD4+ lymphocytes
showed a highly significant increase in the level of sur-
face receptor CCR2 expression in response to the super-
natant of SP-C
A116D expressing cells (Figure 6A). The
same was true in the case of CXCR1, which was
increased on CD4+ lymphocytes after incubation with
the mutant cell supernatant, but remained unaltered on
CD8+ lymphocytes (Figure 6B). We further analyzed the
surface receptor expression on neutrophils. The super-
natant of cells expressing SP-C
A116D increased CXCR1
expression on neutrophils, but did not affect CD11b
levels (Figure 6C). Non-concentrated supernatants gave
the same results by tendency, although less pronounced.
A clear concentration dependency of the effects was
observed (data not shown). This suggests that SP-
C
A116D-expressing MLE-12 cells were able to modulate
the surface receptor expression on the cells of immune
system through the secretion of soluble factors into the
medium.
Discussion
Mutations in the SFTPC gene are a known cause of surfac-
tant deficiency and very variable genetic ILD in children
and adults. We investigated the consequences of the
expression of SP-C with the mutation A116D for cell
homeostasis and signaling in stably transfected MLE-12
cells. We further elucidated the ability of pharmaceutical
drugs used in ILD therapy to modulate some of the cellu-
lar consequences of SP-C deficiency caused by the A116D
mutation.
Table 1 Phospholipid profile of transfected MLE-12 cells expressing mutant SP-C
A116D
Cell lysate Supernatant
WT A116D P WT A116D P
Total phospholipids
(nmol/mg protein)
152.80 ± 9.6 126.50 ± 10.6 0.0334 20.57 ± 3.8 12.90 ± 6.2 0.0259
Phospholipid classes (% of total PL)
Phosphatidylcholine 57.80 ± 1.0 52.80 ± 0.2 < 0.001 44.70 ± 0.1 38.73 ± 0.6 < 0.001
Lyso-Phosphatidylcholine 0.60 ± 0.1 0.90 ± 0.2 0.0171 5.90 ± 0.4 16.78 ± 1.3 0.001
Phosphatidylglycerol 0.30 ± 0.0 0.30 ± 0.0 ns 0.20 ± 0.1 0.10 ± 0.1 ns
Sphingomyelin 6.20 ± 0.3 6.90 ± 0.3 0.0061 8.03 ± 0.2 11.14 ± 0.2 < 0.0001
Ceramide 1.80 ± 0.1 1.60 ± 0.1 0.0133 3.30 ± 0.3 2.15 ± 0.2 0.0034
Glucosyl-Ceramide 0.10 ± 0.0 0.20 ± 0.0 ns 0.08 ± 0.0 0.09 ± 0.0 ns
Phosphatidylethanolamine 11.20 ± 0.5 14.50 ± 0.1 < 0.001 6.54 ± 0.2 6.53 ± 0.1 ns
Phosphatidylserine 6.50 ± 0.1 7.70 ± 0.3 < 0.001 11.71 ± 0.8 8.57 ± 0.1 0.0028
Data are means ± standard deviation from three independent experiments each performed in duplicate. ns = not significant
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A116D led to
the intracellular accumulation of proSP-C
A116D processing
intermediates which were not found in cells transfected
with proSP-C
WT (Figure 1). However, the observed species
resembled those seen in another SP-C mutation, I73T, in
vitro as well as in BAL fluids from patients carrying this
particular mutation [38]. The accumulation we observed in
the case of A116D may thus reflect alterations in folding,
trafficking and/or processing of proSP-C
A116D.T h ef i r s t
step in proSP-C processing is a cleavage at the C-terminal
end [4]. Using an EGFP tag fused to the C-terminus of
proSP-C showed no difference in processing intermediates
of proSP-C
WT and proSP-C
A116D (Figure 1, right). This
suggests that the mutation does not interfere with the
first cleavage step that takes place at the C-terminus.
Furthermore, this finding implies that the mutation does
not abrogate the export from the ER and Golgi completely,
because this cleavage occurs after trafficking through these
compartments [4]. It is not known how the A116D muta-
tion affects the folding of proSP-C, but subtle changes in
conformation may be responsible for the appearance of a
processing intermediate of approx. 17 kDa (Figure 1, band
#3). A similar intermediate can be found in the BAL fluid
of patients with the SP-C
I73T mutation, suggesting that this
Figure 5 Intracellular lipid content and lipid secretion of MLE-12 cells expressing SP-C
WT or SP-C
A116D. (A) Intracellular lipid content of
cells stably expressing WT SP-C or A116D mutant were quantified by mass spectrometry. Untreated cells (-) or cells treated with 10 μM
methylprednisolone (+Met) or hydroxychloroquine (+Hyd) for 24 hours prior to sample isolation. Values were calculated as % of the mean of the
untreated WT values. (B) After removal of detached cells, the lipids in the cell supernatant were analyzed and presented as in (A). The graphs
show relative amounts of phosphatidylcholine and lyso-phosphatidylcholine. Only significant p-values are depicted.
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the mature SP-C that is produced by AT2 cells regardless
of the presence of the I73T mutation [38].
Immunofluorescence assay of stably transfected MLE-12
showed that proSP-C
A116D often colocalized with EEA1
positive vesicles (Figure 2A). Early endosomes generally
contain material that is taken up by endocytosis and is
either recycled or routed for degradation [39]. Up to 80%
of secreted lung surfactant is known to be reinternalized
by AT2 cells from alveolar space [6]. Colocalization of
proSP-C
A116D with EEA1 would thus imply that mutant
protein is secreted together with surfactant and subse-
quently taken up again. On the other hand, while proSP-
C
WT colocalized with syntaxin 2, proSP-C
A116D rarely did
so. Syntaxin 2 is a SNARE protein involved in the secre-
tion of lung surfactant, found in the plasma membrane
and lamellar bodies of AT2 cells. Surfactant secretion is
dependent on the fusion of lamellar bodies with the
plasma membrane, which requires the activity of SNARE
proteins. The lack of colocalization with Syntaxin 2
implies that mutant SP-C mostly does not reach lamellar
bodies. Our results thus suggest that while physiological
proSP-C forms are secreted via lamellar body fusion with
the plasma membrane, proSP-C
A116D might take a differ-
ent route and eventually gets lysosomally degraded.
The expression of mutated proteins frequently results in
elevated cell stress. This has been shown for the SP-C BRI-
CHOS domain mutations L188Q and Δexon4 [14,19]. We
found that the constitutive expression of SP-C
A116D also
significantly increased cell stress, compared to expression
of SP-C
WT. Likewise, the treatment with azathioprine
resulted in an elevated stress level in cells expressing SP-
C
WT as well as in cells expressing the mutant SP-C form
where it further exacerbated cell stress due to the mutated
SP-C. No significant alteration of cell stress was observed
when cells were treated with methylprednisolone, hydro-
xychloroquine or cyclophosphamide. It can thus be con-
cluded that, similar to other BRICHOS domain mutations,
SP-C
A116D leads to elevated cell stress that cannot be cor-
rected by the ILD drugs currently applied. Quite the con-
trary, our data suggest that some substances used in ILD
therapy, especially azathioprine, pose potent stress factors
per se.
After demonstrating that SP-C
A116D expression increases
cell vulnerability to pharmacological stress stimuli, we
further aimed to investigate the underlying intracellular
mechanisms. Chaperone proteins assist in protein folding
and are also involved in the folding of aberrantly processed
proteins. Their synthesis is increased by cells as part of a
cytoprotective mechanism to cope with increased intracel-
lular stress and accumulation of misfolded proteins
[27,40]. Still, without pharmacological boost, such cyto-
protective mechanisms may not always be sufficient to
normalize the cell function and maintain production of
Figure 6 Surface receptor expression on human lymphocytes
and neutrophils. Neutrophils and lymphocytes were isolated from
the whole blood of different human donors and incubated with 7-
fold concentrated supernatants obtained from MLE-12 cells
expressing SP-C
WT or SP-C
A116D prior to flow cytometry analysis.
Non-concentrated supernatants gave the same results, although less
pronounced with a clear concentration dependency of the effects
(data not shown). The receptor levels on the surface of lymphocytes
after incubation with antibodies directed against (A) CCR2 or (B)
CXCR1 are shown and expressed as mean fluorescence intensity
(MFI). Another second marker-specific antibody was applied to
distinguish between CD4+ and CD8+ lymphocytes. (C) The levels of
CXCR1 and CD11b on isolated neutrophils. Significant changes are
depicted with the corresponding p-values.
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position. We investigated the influence of ILD drugs on
the expression of four important chaperones in WT and
A116D cells. The expression of Hsp70, Hsp90 and calreti-
culin was markedly increased in cells expressing
SP-C
A116D (Figure 4A-D). Only in the case of calnexin no
significant increase was observed (Figure 4A). No drug did
affect the expression of any chaperone in a significant
fashion in WT cells. Furthermore, no drug was able to
further increase the elevated chaperone levels seen in cells
expressing A116D. However, azathioprine and methyl-
prednisolone led to a slight, albeit not significant, increase
in the expression of Hsp70 and Hsp90 by A116D cells.
These findings imply that the drugs we tested did not pos-
sess the ability to significantly increase chaperone levels. It
is thus questionable whether they exert their beneficial
effects in ILD treatment by enhancing ER folding capacity.
The packaging and secretion of lung surfactant lipids
is very closely linked to the expression of the hydropho-
bic surfactant proteins in AT2 cells [6]. The lipid com-
position of stably transfected MLE-12 cells was similar
to that previously described for human fetal AT2 cells,
especially with regard to PC composition [41]. In the
cells expressing SP-C
A116D we found a pronounced drop
of total cellular PC, while LPC was increased (Figure
5A, Table 1). It is known that PC is degraded to LPC by
an intrinsic phospholipase A2-like activity, and that LPC
is toxic to various cells [42]. LPC is a known inhibitor
of the lung surfactant activity and has the ability to
penetrate directly into interfacial films to impair lower-
ing of the alveolar surface tension during dynamic com-
pression [43,44]. Elevated LPC levels in the SP-C
A116D-
expressing cells could also explain the heightened sensi-
tivity towards exogenous stress described above. Genera-
tion of LPC cannot account for the decrease of PC mass
in SP-C
A116D expressing cells, but additional factors,
which directly interfere with the synthesis and packaging
of PC, must also be responsible.
Among phospholipids secreted by cells expressing the
A116D mutation into culture supernatant, PC was again
decreased by 14% and LPC was increased by 184%, in
accordance with a reduced surfactant function [41,43].
Treatment with hydroxychloroquine ameliorated the
increase in intracellular and secreted LPC and decrease in
secreted PC, but did not completely correct it (Figure 5).
While methylprednisolone treatment resulted in a reduc-
tion of intracellular LPC, it did not have an effect on PC
levels. The capacity of the treatment with methylpredniso-
lone and hydroxychloroquine to correct the lipid distur-
bances caused by the A116D mutation likely represents
one of the mechanisms by which these treatments are
empirically helpful in some patients with A116D muta-
tions [28] (own unpublished results). However, their mode
of action still remains a conundrum and needs to be inves-
tigated further.
Injury of lung epithelial cells resulting from endogen-
ous or exogenous stress leads to accumulation of pul-
monary leukocytes and finally to inflammation and
tissue remodeling. Leukocytes are attracted to sites of
inflammation along a chemokine gradient. This chemo-
taxis is mediated via chemokine receptors on the surface
of leukocytes [45]. In previous studies we demonstrated
that, among a plethora of chemokine receptors involved
in this network, specifically CCR2 on lymphocytes and
CXCR1 on neutrophils modulate pulmonary immunity
in human inflammatory lung diseases [37,46]. We found
that cells expressing SP-C
A116D released soluble factors
into the medium that increase surface expression of
CCR2 and CXCR1 on CD4+ lymphocytes and CXCR1
on neutrophils (Figure 6A-C). When activated, the high
affinity IL-8 receptor CXCR1 mediates antibacterial kill-
ing capacity [46,47]. Increases in surface expression
levels of CCR2 and CXCR1, respectively, might have the
p o t e n t i a lt om o d u l a t et h ep u l m o n a r yi m m u n er e s p o n s e
with regard to antibacterial (CXCR1) and profibrotic
(CCR2) responses [46,48]. However, the soluble factors
involved in the induction of chemokine receptor expres-
sion as well as the functional consequences of this phe-
nomenon remain to be addressed in future studies.
There are some limitations to our study. A potential lim-
itation is that our system represents a homozygous muta-
tion rather than a heterozygous SFTPC mutation where
one functional allele is still present. However, endogenous
SP-C is expressed in the MLE-12 cells [29]. Although
expression of exogenous SP-C from the CMV promoter
present on the plasmid vector is likely higher, both forms
are present. Given that all known patients with SP-C
mutations are heterozygous carriers, expressing one copy
of the wild type gene, the experimental model closely
reflects the in vivo condition. A second important limita-
tion to consider is that one has to be careful when extra-
polating findings in MLE-12 cells in culture to the actual
alveolar environment. In particular the compositional pro-
file of lipids found in cell culture supernatant is not neces-
sarily representative for surfactant lipids secreted by AT2
cells in vivo as cells in culture may secrete lipids by
mechanisms other than via lamellar bodies. Finally, the
A116D mutation seems to be rare and some of its features
may be specific and not generalizable.
Conclusion
We showed impaired proSP-C processing, elevated cellu-
lar stress and unfavorable changes of the surfactant lipid
composition in a murine alveolar epithelial cell line
expressing mutant SP-C with the BRICHOS domain
mutation A116D. Some of the cellular aspects of disease
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Page 11 of 13we demonstrated could be modulated with drugs used in
the therapy of ILD patients, thus providing insight into
their potential therapeut i cm o d eo fa c t i o n .W ea l s o
showed that MLE-12 cells expressing SP-C
A116D secrete
certain soluble factors that likely promote chemotaxis of
immune cells and may thereby exaggerate inflammatory
and fibrotic processes. Therefore, our study adds to
understanding of the effects that SFTPC mutations
impose on alveolar epithelial cell biology and pave the
way for a more precise pharmacological targeting in
patients with SP-C deficiency.
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